Baseline prevalence of erectile dysfunction in a prostate cancer screening population

Journal of Sexual Medicine

Volumn 5, Issue 2, 2008, Pages 428-435

  Walz, Jochen ^a,b   Perrotte, Paul ^c   Suardi, Nazareno ^a,d   Hutterer, Georg ^a   Jeldres, Claudio ^a   Bénard, Francois ^c   Valiquette, Luc ^c   Graefen, Markus ^b   Montorsi, Francesco ^d   Karakiewicz, Pierre I ^a,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Baseline; Erectile dysfunction; IIEF; Prostate Cancer; Screening

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EDUCATIONAL STATUS; ERECTILE DYSFUNCTION; HEALTH PROMOTION; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SOCIAL BEHAVIOR;

EID: 38649087024     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00662.x     Document Type: Article

References (29)

1. Michl UH, Friedrich MG, Graefen M, Haese A, Heinzer H, Huland H. Prediction of postoperative sexual function after nerve sparing radical retropubic prostatectomy. J Urol 2006;176:227-31.
2. Dubbelman YD, Dohle GR, Schroder FH. Sexual function before and after radical retropubic prostatectomy: A systematic review of prognostic indicators for a successful outcome. Eur Urol 2006;50:711-8, discussion 718-20.
3. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51.
4. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55:58-61.
5. Beard CJ, Lamb C, Buswell L, Schneider L, Propert KJ, Gladstone D, D'Amico A, Kaplan I. Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:257-62.
6. Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Soloway MS. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
7. Salonia A, Zanni G, Gallina A, Sacca A, Sangalli M, Naspro R, Briganti A, Farina E, Roscigno M, Dapozzo LF, Rigatti P, Montorsi F. Baseline potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. Eur Urol 2006;50:360-5.
8. Karakiewicz PI, Aprikian AG, Bazinet M, Elhilali MM. Patient attitudes regarding treatment-related erectile dysfunction at time of early detection of prostate cancer. Urology 1997;50:704-9.
9. Briganti A, Gallina A, Salonia A, Farina E, Zanni G, Rigatti P, Montorsi F. Reliability of classification of erectile function domain of the international index of erectile function in patients affected by localized prostate cancer who are candidates for radical prostatectomy. Urology 2005;66:1140, -author reply 1140 -1.
10. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005;47:80-5.
11. Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D. Prevalence of erectile dysfunction among young adults: Results of a large-scale survey. J Sex Med 2004;1:284-91.
12. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: From the male attitudes regarding sexual health survey. J Sex Med 2007;4:57-65.
13. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M. Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004;171:1513-9.
14. Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006;175:99-103.
15. Remennick LI. Preventive behavior among recent immigrants: Russian-speaking women and cancer screening in Israel. Soc Sci Med 1999;48:1669-84.
16. Alcaraz M, Lluch A, Miranda J, Pereiro I, Salas MD. Study of non-participation in the breast cancer screening program in the city of Valencia (Spain). Gac Sanit 2002;16:230-5.
17. Escoyez B, Mairiaux P. Breast and cervical cancer screening: Beliefs and behaviors among the female population of the city of Liege (Belgium). Rev Med Liege 2003;58:319-26.
18. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-51.
19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
20. Karakiewicz P, Shariat SF, Naderi A, Kadmon D, Slawin KM. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. Urology 2005;65:131-5.
21. Lewinshtein DJ, Perrotte P, Lebeau T, Ramirez A, Benayoun S, Karakiewicz PI. Normal urinary and sexual function in men without evidence of prostate cancer from Montreal, Canada. BJU Int 2006;97:1273-7.
22. McCammon KA, Kolm P, Main B, Schellhammer PF. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999;54:509-16.
23. Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, Zoccoli J, Defoy I. The prevalence of erectile dysfunction in the primary care setting: Importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006;166:213-9.
24. Blanker MH, Groeneveld FP, Prins A, Bernsen RM, Bohnen AM, Bosch JL. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: The Krimpen study of male urogenital tract problems and general health status. BJU Int 2000;85:665-71.
25. International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists. Lancet 1999;354:533-40.
26. Hoesl CE, Woll EM, Burkart M, Altwein JE. Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005;47:511-7.
27. Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: Results from the Erectile Dysfunction Observational Study (EDOS). Eur Urol 2007;51:541-50.
28. Mulhall J, Land S, Parker M, Waters W, Flanigan R. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005;2:532-40.
29. Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: A systematic review of clinical data. J Sex Med 2005;2:658-67.